A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer.

A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer.

Publication date: Mar 22, 2019

Targeted therapies have become the focus of much of the cancer therapy research conducted in the United States. While these therapies have made vast improvements in the treatment of cancer, their results have been somewhat disappointing due to acquired resistances, high cost, and limited populations of susceptible patients. As a result, targeted therapeutics are often combined with other targeted therapeutics or chemotherapies. Compounds which target more than one cancer related pathway are rare, but have the potential to synergize multiple components of therapeutic cocktails. Natural products, as opposed to targeted therapies, typically interact with multiple cellular targets simultaneously, making them a potential source of synergistic cancer treatments. In this study, a rare natural product, deacetylnemorone, was shown to inhibit cell growth in a broad spectrum of cancer cell lines, selectively induce cell death in melanoma cells, and inhibit angiogenesis and invasion. Combined, these results demonstrate that deacetylnemorone affects multiple cancer-related targets associated with tumor growth, drug resistance, and metastasis. Thus, the multi-targeting natural product, deacetylnemorone, has the potential to enhance the efficacy of current cancer treatments as well as reduce commonly acquired treatment resistance.

Open Access PDF

Taylor, W.F., Moghadam, S.E., Moridi Farimani, M., N Ebrahimi, S., Tabefam, M., and Jabbarzadeh, E. A multi-targeting natural compound with growth inhibitory and anti-angiogenic properties re-sensitizes chemotherapy resistant cancer. 22931. 2019 PLoS One (14):6.

Concepts Keywords
Angiogenesis Death melanoma
Angiogenic Chemotherapy
Cancer Chemotherapies
Chemotherapies Medicine
Chemotherapy Clinical medicine
Drug Resistance Health
Interact Antineoplastic drugs
Melanoma Oncology
Metastasis Cancer treatments
Natural Product Targeted therapy
Spectrum Chemotherapy
Synergistic Drug resistance
Targeted Therapies Antineoplastic resistance
Tumor Chemotherapy
United States

Semantics

Type Source Name
gene UNIPROT PDLIM5
gene UNIPROT NAA50
drug DRUGBANK Nonoxynol-9
gene UNIPROT VAMP3
gene UNIPROT ARTN
gene UNIPROT AGRP
drug DRUGBANK Thymidine monophosphate
gene UNIPROT ACSS2
gene UNIPROT ACCS
gene UNIPROT PLA2G15
drug DRUGBANK Resveratrol
gene UNIPROT KRT10
gene UNIPROT DYRK3
gene UNIPROT IK
gene UNIPROT SELENBP1
gene UNIPROT RNMT
gene UNIPROT MET
gene UNIPROT SLTM
drug DRUGBANK Methionine
gene UNIPROT FOXD3
gene UNIPROT HGF
gene UNIPROT IL6
gene UNIPROT SOS1
gene UNIPROT INTU
gene UNIPROT EPHB2
gene UNIPROT MAPK1
gene UNIPROT MTOR
gene UNIPROT MOK
gene UNIPROT MCPH1
gene UNIPROT MCAT
gene UNIPROT SLC16A1
drug DRUGBANK Medium-chain triglycerides
gene UNIPROT NSMAF
gene UNIPROT CNTRL
drug DRUGBANK Emodin
drug DRUGBANK Curcumin
gene UNIPROT DES
drug DRUGBANK Diethylstilbestrol
gene UNIPROT SOD1
gene UNIPROT IGFALS
disease DOID als
gene UNIPROT WARS
disease MESH hypoxia
drug DRUGBANK Oxygen
gene UNIPROT MBNL1
gene UNIPROT PROC
gene UNIPROT LAMC2
gene UNIPROT CSF2
gene UNIPROT EGFR
disease DOID syndrome
disease MESH syndrome
drug DRUGBANK Myricetin
drug DRUGBANK Chlorogenic Acid
gene UNIPROT COL9A3
gene UNIPROT COMP
gene UNIPROT COL9A1
gene UNIPROT COL9A2
gene UNIPROT SCN8A
gene UNIPROT AKT1
gene UNIPROT PIK3CG
gene UNIPROT PIK3CB
gene UNIPROT PIK3CD
gene UNIPROT PIK3CA
gene UNIPROT GLI3
gene UNIPROT PAPPA
drug DRUGBANK Ribociclib
drug DRUGBANK Palbociclib
pathway BSID Breast cancer
disease DOID breast cancer
disease MESH breast cancer
disease DOID NSCLC
gene UNIPROT CTLA4
gene UNIPROT BRD2
gene UNIPROT TNIP1
gene UNIPROT DUOXA1
gene UNIPROT RBM8A
gene UNIPROT SLC22A3
gene UNIPROT ITK
gene UNIPROT MAGEE1
gene UNIPROT MENT
drug DRUGBANK Trestolone
gene UNIPROT RXFP2
gene UNIPROT NOVA2
disease DOID noma
disease MESH noma
gene UNIPROT NR1H4
gene UNIPROT ADRB2
gene UNIPROT BFAR
gene UNIPROT WIPF1
pathway BSID M Phase
pathway BSID S Phase
disease DOID lung cancer
disease MESH lung cancer
gene UNIPROT ARID3A
gene UNIPROT ARID1B
drug DRUGBANK Aspartame
disease DOID ovarian cancer
disease MESH ovarian cancer
drug DRUGBANK Medical air
disease MESH separated
gene UNIPROT RASA1
gene UNIPROT RGS6
gene UNIPROT LSR
drug DRUGBANK Water
drug DRUGBANK Ethanol
gene UNIPROT CES2
gene UNIPROT CASP1
gene UNIPROT RAB8A
pathway BSID Cell Cycle
pathway BSID Cell cycle
drug DRUGBANK Sodium bicarbonate
drug DRUGBANK Edetic Acid
drug DRUGBANK Ethylenediamine
drug DRUGBANK Trypsin
gene UNIPROT TSPO
gene UNIPROT CHRM3
gene UNIPROT COL17A1
gene UNIPROT TIMM8A
gene UNIPROT C2
gene UNIPROT KIT
drug DRUGBANK L-Glutamine
drug DRUGBANK Streptomycin
drug DRUGBANK Methylergometrine
disease DOID ovarian carcinoma
drug DRUGBANK Doxorubicin
disease DOID colorectal carcinoma
disease MESH colorectal carcinoma
disease DOID ovarian adenocarcinoma
disease DOID osteosarcoma
disease MESH osteosarcoma
gene UNIPROT STIP1
gene UNIPROT ST13
gene UNIPROT HOPX
drug DRUGBANK Dimethyl sulfoxide
gene UNIPROT FEZF2
gene UNIPROT GATA4
gene UNIPROT FBN1
gene UNIPROT DEPP1
gene UNIPROT GOPC
drug DRUGBANK Flunarizine
gene UNIPROT SNAP25
gene UNIPROT HERPUD1
gene UNIPROT VEGFA
drug DRUGBANK Paclitaxel
pathway BSID Apoptosis
gene UNIPROT PHEX
disease MESH hyp
drug DRUGBANK Nivolumab
drug DRUGBANK Tisagenlecleucel
drug DRUGBANK Spinosad
gene UNIPROT SMIM10L2A
gene UNIPROT SMIM10L2B
drug DRUGBANK Aflibercept
drug DRUGBANK Sorafenib
drug DRUGBANK Bevacizumab
drug DRUGBANK L-Tyrosine
gene UNIPROT TRIM13
gene UNIPROT CXADR
gene UNIPROT CASR
gene UNIPROT NR1I3
gene UNIPROT PRKAR1A
gene UNIPROT SPG7
gene UNIPROT TPPP3
gene UNIPROT CEP55
disease MESH death
drug DRUGBANK Coenzyme M
gene UNIPROT ZFYVE9
gene UNIPROT SAR1A
disease MESH metastasis
pathway BSID Angiogenesis
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease MESH multiple
disease DOID cancer
disease MESH cancer
disease MESH growth
disease MESH multi

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *